The Conjunctivitis Treatment Market is projected to grow from USD 4.76 billion in 2024 to USD 6.24 billion by 2032, with a CAGR of 4.53%. Increasing awareness, OTC availability, and advancements in drug formulations are driving market growth. The U.S. market is expected to reach USD 2.14 billion by 2032, with a CAGR of 4.18%. Major players include Novartis AG, AbbVie Inc., Bausch + Lomb, and more.

The anti-allergic segment dominated the market in 2024, with a 41.25% share due to rising allergic conjunctivitis cases. Eye drops, the preferred formulation, held a 68.25% market share for its direct application and efficiency. The topical segment, with a 76.4% market share, provides rapid therapeutic effects with fewer systemic side effects.

North America leads the global market with a 46.3% share in 2024, driven by robust healthcare infrastructure and high awareness. Asia Pacific is expected to record the fastest growth due to factors like urbanization, pollution, and increased patient population. Efforts to improve healthcare access and focus on eye health contribute to market expansion.

SNS Insider offers a detailed briefing session with analysts and a report on the Conjunctivitis Treatment Market, including market size, regional analysis, segment insights, and competitive landscape. For more information, visit their website and explore related reports on ophthalmic drugs and topical drug delivery markets.

Read more at GlobeNewswire: Conjunctivitis Treatment Market to Reach USD 6.24 Billion